Pfizer has agreed to acquire a biomanufacturing facility in Sanford, North Carolina from Abzena, a San Diego, California-based CDMO of biologics and antibody drug conjugates,  

The new Sanford, North Carolina site is expected to employ approximately 300 employees by 2025, including the current staff of approximately 100 employees, which is expected to bring Pfizer’s total workforce in North Carolina to more than 4,500 employees. Since 2017, Pfizer has invested more than $5 billion to support the ongoing growth of its manufacturing footprint in the US, with $1.4 billion invested in North Carolina. 

In addition, Abzena and Pfizer’s CentreOne contract manufacturing organization will collaborate to advance complex biologic products to market. 

The transaction is expected to close in the first quarter of 2023, subject to customary closing conditions.  

Source: Abzena